- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
CRISIL Ratings reaffirmed Balaxi Pharma's long-term bank facilities at 'CRISIL BBB+' but revised its outlook from 'Stable' to 'Negative'. This change reflects expected pressure on profitability due to increased sales & marketing expenditure for institutional sales and an elongated working capital cycle. The rating affirmation acknowledges Balaxi's established market position.